India, Aug. 6 -- ADMA Biologics, Inc. (ADMA) reported second-quarter financial results reflecting improved earnings, supported by revenue growth driven by ASCENIV sales. In addition, the company reiterated revenue guidance for the whole year of 2026.
Following the news, ADMA is up over 9.02% at $10.10 in the market.
Company Profile
ADMA Biologics develops speciality biologics for the treatment of immunodeficient patients at risk for infection and for infectious diseases.
The lead product candidates of the firm include ASCENIV, approved for the treatment of primary humoral immunodeficiency (PI) or primary immune deficiency disease (PIDD), in adults and children (2 to 17 years of age), BIVIGAM, approved for PI and NABI-HB (hepatitis B imm...